Data protection Impressum

Life sciences

The latest collaboration complements Vaxcyte’s strategy to commence the initial commercial launch of VAX-24, a vaccine that targets the prevention of invasive pneumococcal disease (IPD).

Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine

17 October 2023

Mimix’s objective, as outlined in its strategic vision, is to introduce this wound care product to the US market by the second half of 2024.

Mimix Biotherapeutics’ breakthrough tissue regeneration treatment receives strategic investment

17 October 2023

The third building of the site was inaugurated in the presence (from left to right) of Stéphane Coppey, the President of the City of Monthey, Christophe Darbellay, Head of the Department of Economy and Education, and Jean-Marc Tornare, President of BioArk.

BioArk Monthey’s third building signifies exponential growth in the life sciences sector

16 October 2023

CDMOs play a crucial role in the pharmaceutical sector, serving as key partners in the drug development and production process.

Siegfried and Lonza secure top positions in global pharmaceutical outsourcing rankings

16 October 2023

Adiposs pioneers a new era in cancer patient care with a pivotal leap towards making ImageBAT a revolutionary tool in detecting hypermetabolism.

Adiposs completes the phase I clinical trial of its flagship product ImageBAT

11 October 2023

PULSE, with its distinctive amalgamation of adaptable, future-proof infrastructure, is set to become a pivotal hub designed to uplift and expand the frontiers of biotech and various scientific ventures.

PULSE, a modular innovation center in the heart of the Health Valley

10 October 2023

Through this partnership, the synergy between academic excellence and pioneering biotherapeutic research is set to delineate new horizons in patient care, particularly in the field of tissue regeneration and repair.

Orio Therapeutics partners with Australia’s largest University to transform regenerative medicine

10 October 2023

Lonza continues to fortify its position in ADC production, expanding collaboration and infrastructure to enhance its acclaimed Ibex Dedicate Biopark.

Lonza further extends its ADC manufacturing capabilities in Visp

9 October 2023

The Institute of Life Technologies of the HES-SO Valais/Wallis has forged a five-year collaboration with Debiopharm Research & Manufacturing to develop new targeted antibody fragment vectorization technologies.

HES-SO Valais-Wallis and Debiopharm partner up to battle cancer

4 October 2023

Nagi Bioscience is at the cusp of redefining the landscape of next-generation drug discovery and chemical testing technologies, placing humane testing solutions within arm’s reach of the global scientific community.

Nagi Bioscience secures CHF 12.4 million to propel animal-alternative testing

3 October 2023

1 … 14 15 16 17 18 19 20 21 22 … 42